Ivarmacitinib sulfateProduct ingredient for Ivarmacitinib

Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,^11,14,16 ankylosing spondylitis,⁷ rheumatoid arthritis,⁸ psoriatic arthritis,⁹ graft-versus-host disease,^2,10 vitiligo,¹² ulcerative colitis,¹³ alopecia areata,¹⁵ and primary membranous nephropathy.¹⁷